HLOC
GILD icon

H.L. Ormond & Company’s Gilead Sciences GILD Stock Holding History

H.L. Ormond & Company’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$629K Buy
10,188
+780
+8% +$49.2K 1.01% 48
2022
Q2 		$582K Sell
9,408
-1,208
-11% -$74.8K 0.94% 55
2022
Q1 		$631K Buy
10,616
+215
+2% +$13.7K 0.77% 61
2021
Q4 		$662K Buy
+10,401
New +$716K 0.78% 59

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

H.L. Ormond & Company's GILD Position: Q3 2022 in Review

H.L. Ormond & Company increased its Gilead Sciences (GILD) stake by 8.3% in Q3 2022, buying an estimated $49.2K and bringing the position to 10,188 shares worth $629K. The position accounts for 1.01% of the portfolio, ranked #48.

H.L. Ormond & Company first reported a position in GILD in Q4 2021 and has held it in 4 quarters since. The position peaked at $662K in Q4 2021. 1,602 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

  • H.L. Ormond & Company held 10,188 shares of Gilead Sciences worth $629K as of Q3 2022.
  • H.L. Ormond & Company bought 780 Gilead Sciences shares in Q3 2022, an estimated $49.2K.
  • Gilead Sciences made up 1.01% of H.L. Ormond & Company's portfolio in Q3 2022, its #48 holding.
  • H.L. Ormond & Company first reported a position in Gilead Sciences in Q4 2021 and has held it in 4 quarters since.
  • H.L. Ormond & Company's Gilead Sciences position peaked at $662K in Q4 2021.
  • 1,602 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on H.L. Ormond & Company's 13F filing for Q3 2022, filed 14 Nov 2022.